|

NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT

NEW MindMed MDMA trials, Compass Pathways Patent, Small Pharma DMT Trials Begins | MNMD, CMPS, DMT

What’s up psychedelic investors! We have been seeing a lot of red in the last few months. Companies like MindMed (MNMD: NASDAQ) (MMED:NEO), Compass Pathways (CMPS: NASDAQ) &Small Pharma ( OTC: DMTTF) ( CVE: DMT) have had huge news in the last week. So in this episode we’ll be covering the major news surrounding these psychedelic stocks!

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #CompassPathways #PsychedelicStocks

Similar Posts

  • Compass Pathways Q4 Earnings Call Highlights [Is CMPS Closing In On MindMed?]

    Hey guys! I promised ya’ll that I will keep you updated on Compass Pathways (NASDAQ: CMPS) earnings call. There has been some pretty interesting developments on the company that I thought I should Bring to your attention. Compass Pathways is one of the psychedelic companies that is the furthest advanced in their clinical trials (Phase IIB to treat TRD). However, I wasn’t aware that they are doing a LOT more. This is quite interesting because in my opinion, CMPS is not a one trick pony anymore and it might as well be in direct competition with my favorite company in this sector (MindMed).

    In this video, we’ll cover:
    1. Compass Pathways’ Financials
    2. Their IP
    3. Therapists Training
    4. Future Projects
    5. Digital Technology

    I hope that this is not going to enrage the MindMed fan boys out there. I just thought that it might be interesting for some of you psychedelic investors.
    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
    https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #CompassPathways #CMPS #MindMed

  • Numinus & Cybin Forge MASSIVE DEALS ( NUMI / CYBN )

    BIG news for Cybin Inc. (CYBN: NEO) (CLXPF: OTC) and Numinus Wellness (NUMI: NEO)
    (LKYSF: OTC).

    First and foremost, Numinus announced that the company acquired NCT, a Toronto-based, fully operational neurology center with 13 doctors, 8 allied health staff, nurse practitioners, and physician assistants. NCT and Numinus plan to establish the first center for excellence in psychedelic neurology.

    Speaking of centers of excellence, Cybin entered into an agreement with a company called Greenbrook TMS to establish mental health centers of excellence in order to facilitate R & D of psychedelic compound-based therapeutics for patients suffering from depression.

    Why is this big news? Watch till the end to find out!

    In other news, we are glad to announce that The Psychedelic Investor has entered into a collaboration with Psychedelic Spotlight, one of the biggest news sources for psychedelic-related news.

    Twice a month, I will be discussing some of the major industry news among other psychedelic industry experts in Psychedelic Spotlight’s segment titled: “Spotlight Roundup”.

    Check out my first appearance on their podcast by clicking the link below!
    https://www.youtube.com/watch?v=UKGFXnsOlr8

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Timestamps
    0:00 -Intro
    2:40 – Numinus Acquisition of Neurology Center of Toronto
    9:55 -Cybin Enters Agreement with Greenbrook

    Links:

    NUMINUS WELLNESS TO ACQUIRE NEUROLOGY CENTRE OF TORONTO, PLANS TO CREATE CENTRE FOR PSYCHEDELIC NEUROLOGY:
    https://thepsychedelicinvestor.com/2021/07/06/numinus-wellness-to-acquire-neurology-centre-of-toronto-plans-to-create-centre-for-psychedelic-neurology/

    CYBIN (NEO: CYBN, OTC: CLXPF) ENTERS INTO COLLABORATION AGREEMENT WITH GREENBROOK TMS TO ESTABLISH MENTAL HEALTH CENTERS OF EXCELLENCE:
    https://thepsychedelicinvestor.com/2021/07/08/cybin-enters-into-collaboration-agreement-with-greenbrook-tms-to-establish-mental-health-centers-of-excellence/

    Enjoy the episode!

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #Numinus #Cybin #NUMIStock

  • MindMed’s Q2 Earnings Call: What does the future hold for MNMD/ MMED?

    Check out atai Life Sciences’ earnings call: https://www.youtube.com/watch?v=lkE3EmU0o_w

    What’s up psychedelic stocks investors?!? Today marked MindMed’s (MNMD /MMED) Second Quarter 2021 conference call. In the conference call, MindMed gave updates on their varying projects, such as treating anxiety with LSD, addiction with 18MC, and pain with LSD. They also give insights into their digital medicines division and gave an update on their hiring spree.

    This Kevin O’Leary-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 17+ different projects under their belt, MindMed is one of the most exciting companies to keep an eye on in the industry.

    This conference call can help investors answer the questions: is MNMD stock a good investment? Will MMED go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?

    Enjoy the episode!

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Check out our website: thepsychedelicinvestor.com

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    #MindMed #MNMD #PsychedelicStocks